Evaluation of Overactive Bladder in Male Antidepressant Users: A Prospective Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: In this study, we investigated overactive bladder (OAB) functions in male patients who used antidepressant drugs (ADs) that were previously examined in female patients, based on conflicting data in literature regarding the effects of AD on OAB and the differences between male and female urinary system physiologies (anatomical and hormonal). Methods: The study included 202 male patients (a control group of 90 healthy subjects, and an experimental group of 112 patients taking ADs for different disorders). All the patients completed the overactive bladder-validated 8 (OAB-V8) questionnaire, the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), and the Beck Depression Inventory (BDS). Results: The OAB-V8, ICIQ-SF, and BDS scores for the antidepressant users were significantly higher than those of the control group. The highest prevalence of OAB symptoms was observed in patients taking venlafaxine (68.2%), and the lowest prevalence was in patients taking sertraline (28.0%). Moreover, the frequency of OAB between the antidepressant groups was statistically significant. The univariate logistic regression analyses showed a significant relationship between the presence of OAB, antidepressant usage, BDS score, and the age of a patient. In the multivariate logistic regression analyses, the association between the presence of OAB and antidepressant usage was statistically significant. Conclusions: The present study showed that the incidence of OAB and the severity of OAB symptoms increased in males using antidepressants for various disorders. This may have been due to unique pharmacological effects, on a molecular or individual level, of serotonin-norepinephrine reuptake inhibitors.
Abstract
Purpose: In this study, we investigated overactive bladder (OAB) functions in male patients who used antidepressant drugs (ADs) that were previously examined in female patients, based on conflicting data in literature regarding the effects of AD on OAB and the differences between male and female urinary system physiologies (anatomical and hormonal). Methods: The study included 202 male patients (a control group of 90 healthy subjects, and an experimental group of 112 patients taking ADs for different disorders). All the patients completed the overactive bladder-validated 8 (OAB-V8) questionnaire, the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), and the Beck Depression Inventory (BDS). Results: The OAB-V8, ICIQ-SF, and BDS scores for the antidepressant users were significantly higher than those of the control group. The highest prevalence of OAB symptoms was observed in patients taking venlafaxine (68.2%), and the lowest prevalence was in patients taking sertraline (28.0%). Moreover, the frequency of OAB between the antidepressant groups was statistically significant. The univariate logistic regression analyses showed a significant relationship between the presence of OAB, antidepressant usage, BDS score, and the age of a patient. In the multivariate logistic regression analyses, the association between the presence of OAB and antidepressant usage was statistically significant. Conclusions: The present study showed that the incidence of OAB and the severity of OAB symptoms increased in males using antidepressants for various disorders. This may have been due to unique pharmacological effects, on a molecular or individual level, of serotonin-norepinephrine reuptake inhibitors.
참고문헌 (32)
- Abrams P, "Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence", Neurourol Urodyn, 29, pp.213~240 (2010)
- Stewart WF, "Prevalence and burden of overactive bladder in the United States", World J Urol, 20, pp.327~336 (2003)
- Coyne KS, "National community prevalence of overactive bladder in the Unit ed States stratified by sex and age", Urology, 77, pp.1081~1087 (2011)
- Chapple C., "Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of “overactive bladder”", Neurourol Urodyn, 33(Suppl 3), pp.S6~S13 (2014)
- Geddes JR, "Relapse prevention with antidepressant drug treatment in depressive disorders : a systematic review", Lancet, 361, pp.653~661 (2003)
- den Boer JA, "Biological dissection of anxiety disorders : the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine", Int Clin Psychopharmacol, 9(Suppl 4), pp.47~52 (1995)
- Lindsley CW, "The top prescription drugs of 2011 in the United States : antipsychotics and antidepressants once again lead CNS therapeutics", ACS Chem Neurosci, 3, pp.630~631 (2012)
- Kyle CJ, "Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice", Depress Anxiety, 8, pp.147~153 (1998)
- Hay-Smith J, "Which anticholinergic drug for overactive bladder symptoms in adults", Cochrane Database Syst Rev, (3), pp.CD005429~ (2005)
- Asplund R, "Nocturia, depression and antidepressant medication", BJU Int, 95, pp.820~823 (2005)
- Movig KL, "Selective serotonin reuptake inhibitor-induced urinary incontinence", Pharmacoepidemiol Drug Saf, 11, pp.271~279 (2002)
- Albayrak S, "Assessment of overactive bladder in women antidepressant users", Int Urol Nephrol, 47, pp.1479~1484 (2015)
- Tarcan T, "OAB-V8 Aşırı aktif mesane sorgulama formu validasyon çalışması", Üroloji Bülteni, 21, pp.113~116 (2012)
- Cetinel B, "The validation study of ICIQ-SF Turkish version", Turk J Urol, 30, pp.332~338 (2004)
- Beck AT, "An inventory for measuring depression", Arch Gen Psychiatry, 4, pp.561~571 (1961)
- Guay DR, "Duloxetine for management of stress urinary incontinence", Am J Geriatr Pharmacother, 3, pp.25~38 (2005)
- Chancellor M, "Anticholinergics for overactive bladder therapy : central nervous system effects", CNS Neurosci Ther, 18, pp.167~174 (2012)
- Wuerstle MC, "Contribution of common medications to lower urinary tract symptoms in men", Arch Intern Med, 171, pp.1680~1682 (2011)
- Tonini M, "5-HT4 receptor agonists and bladder disorders", Trends Pharmacol Sci, 17, pp.314~316 (1996)
- Bär KJ, "The influence of major depression and its treatment on heart rate variability and pupillary light reflex parameters", J Affect Disord, 82, pp.245~252 (2004)
- Andersson KE, "Treatment of the overactive bladder: possible central nervous system drug targets", Urology, 59(5 Suppl 1), pp.18~24 (2002)
- Tikkinen KA, "A systematic evaluation of factors associated with nocturia--the population-based FINNO study", Am J Epidemiol, 170, pp.361~368 (2009)
- Votolato NA, "Serotonergic antidepressants and urinary incontinence", Int Urogynecol J Pelvic Floor Dysfunct, 11, pp.386~388 (2000)
- van Kerrebroeck P, "Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence", BJOG, 111, pp.249~257 (2004)
- Viktrup L, "Pharmacological agents used for the treatment of stress urinary incontinence in women", Curr Med Res Opin, 19, pp.485~490 (2003)
- Cheng CL, "Role of 5-HT1A receptors in control of lower urinary tract function in anesthetized rats", Am J Physiol Renal Physiol, 298, pp.F771~F778 (2010)
- Polimeni G, "Venlafaxine-induced urinary incontinence resolved after switching to sertraline", Clin Neuropharmacol, 28, pp.247~248 (2005)
- Tonini M, "Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle", Br J Pharmacol, 113, pp.1~2 (1994)
- Tatsumi M, "Pharmacological profile of antidepressants and related compounds at human monoamine transporters", Eur J Pharmacol, 340, pp.249~258 (1997)
- Perry S, "Leicestershire MRC Incontinence Study Group. An investigation of the relationship between anxiety and depression and urge incontinence in women: development of a psychological model", Br J Health Psychol, 11(Pt 3), pp.463~482 (2006)
- Milsom I, "Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS", Urology, 80, pp.90~96 (2012)
- Selvaraj J, "Symptoms, prevalence, and risk factors of overactive bladder in women in south India", Int J Gynaecol Obstet, 129, pp.274~275 (2015)